Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
Top Cited Papers
- 2 April 2021
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in Morbidity and Mortality Weekly Report (MMWR)
- Vol. 70 (13), 495-500
- https://doi.org/10.15585/mmwr.mm7013e3
Abstract
MRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection was 90% for full immunization (≥14 days after second dose) and 80% for partial immunization (≥14 days after first dose but before second dose) in real-world conditions.Keywords
This publication has 7 references indexed in Scilit:
- Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical CenterThe New England Journal of Medicine, 2021
- SARS-CoV-2 Infection after Vaccination in Health Care Workers in CaliforniaThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2021
- Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipientsThe Lancet, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 InfectionJAMA Network Open, 2020